Statements and Testimony - 2001

  • October 9, 2001 - Biological Weapons Control Testimony: Recommendations for Federal Funding of Public Health Activities
    On October 9, 2001, Dr. Michael Osterholm, Director of Center for Disease Research and Policy, University of Minnesota, and Chair of the PSAB Committee on Public Health, testified before the Senate Committee on Health, Education, Labor, and Pensions, for a hearing on Effective Resposnes to the Threat of Bioterrorism. His testimony described the budget recommendations of a Working Group on Bioterrorism Preparedness, including the American Society for Microbiology, for public and private laboratories, hospitals, and federal, state and local public health agencies to effectively recognize and respond to the threat of bioterrorism.
  • September 17, 2001 - CDC Funding for FY 2002
    The ASM sent a letter to the Chair and Ranking Minority members of the House and Senate Labor, Health and Human Services and Education Appropriations Subcommittees, urging funding for infectious disease programs and activities of the Centers for Disease Control and Prevention, in FY 2002.
  • August 14, 2001 - ASM Comments on OMB Proposed Data Quality Guidelines
    The ASM submitted comments to the Office of Management and Budget in response to "Proposed Guidelines for Ensuring and Maximizing the Quality, Objectivity, Utility, and Integrity of Information Disseminated by Federal Agencies" which were published in the June 28, 2001 Federal Register.
  • July 30, 2001 - In Vitro Diagnostic Devices Pertaining to Hepatitis C Viruses (HCV)
    The ASM provided comments to the Food and Drug Administration (FDA) on its Draft Guidance Document for Industry and FDA on Premarket Approval Applications for In Vitro Diagnostic Devices Pertaining to Hepatitis C Viruses (HCV): Assays Intended for Diagnosis, Prognosis, or Monitoring of HCV Infection, Hepatitis C, or Other HCV-associated Disease.
  • July 13, 2001 - Risk Management Action Plan for Foodborne Listeria Monocytogenes
    The ASM submitted comments on the Food and Drug Administration's and U.S. Department of Agriculture's draft Risk Assessment Document and Risk Management Action Plan for relative risk to public health from foodborne Listeria monocytogenes in ready-to-eat foods, which was published in the January 19, 2001 Federal Register.
  • June 28, 2001 - Funding to Combat Antimicrobial Resistance
    The ASM sent a letter to Representative Sherrod Brown (D-OH) in support of his bill, "The Antimicrobial Resistance Prevention Act of 2001" which would provide funding for the coordinated efforts of federal agencies, including the Centers for Disease Control and Prevention, the National Institutes of Health, the Food and Drug Administration, the Department of Agriculture and others, to combat antimicrobial resistance.
  • June 12, 2001 - Strengthening Science at the EPA Bill
    The ASM sent a letter to Congressman Vernon Ehlers (R-MI) on June 12 endorsing legislation introduced on May 17 to address the insufficient role science plays in regulatory decisions at the EPA. The "Strengthening Science at the Environmental Protection Agency Act" H.R. 64 implements the two primary recommendations of a National Research Council (NRC) report on the use and practice of science within the EPA.
  • May 30, 2001 - FDA Draft Guidance Document Regarding Lab Tests
    The ASM submitted comments to the FDA on its draft Guidance Document regarding the criteria used to determine whether specific laboratory tests are waived from certain requirements of the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The FDA draft Guidance Document was published in the Federal Register on March 1.
  • May 1, 2001 - National Institutes of Health Plan for Trainees
    The ASM's Public and Scientific Affairs Board sent comments to the National Institutes of Health (NIH) supporting its plans to implement certain recommendations of the National Academy of Sciences (NAS) report "Addressing the Nation's Needs for Biomedical and Behavioral Scientists."